Piper Jaffray Upgrades Cytokinetics (CYTK) to Overweight; Sees 100% Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
February 13, 2015 8:29 AM ESTRoth Capital comments on Cytokinetics (Nasdaq: CYTK) following Q4, FY14 results reported late Thursday. The firm retains a Buy rating and $18 price target on Cytokinetics following the numbers and update.
Analyst Joseph Pantginis noted that Cytokinetics reported FY14 loss of $0.41 per share with revenue of $46.9 million, versus the firm's... More
Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook
February 12, 2015 4:13 PM ESTCytokinetics (NASDAQ: CYTK) reported Q4 EPS of $0.23, $0.40 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $21.8 million versus the consensus estimate of $10.8 million.
Financial Guidance
Cytokinetics also announced its financial guidance for 2015. The company anticipates cash... More
